Bladder Cancer Combination Therapy Granted Priority Review

The FDA is reviewing a new combination treatment for patients unable to receive cisplatin-based chemotherapy.

Updated on Oct. 2, 2026 in Cancer

Bold flat-color editorial illustration featuring a glass vial and protein structure, symbolizing pharmaceutical regulatory review and oncology research. — The FDA has granted Priority Review to a new drug regimen combining durvalumab and enfortumab vedotin for muscle-invasive bladder cancer patients. AI Illustration. Upload story photo >

Live Poll

Do you trust that new immunotherapy drug combinations offer better treatment outcomes than traditional surgery alone?

The FDA has granted Priority Review to a new drug regimen combining durvalumab and enfortumab vedotin for the treatment of muscle-invasive bladder cancer. This pathway accelerates the regulatory process for patients who are ineligible for or have declined standard cisplatin-based chemotherapy.

Why it matters

This application aims to provide a new therapeutic option for individuals who cannot tolerate traditional chemotherapy, which remains the standard of care for muscle-invasive bladder cancer. By targeting specific proteins in these patients, the treatment seeks to improve long-term outcomes while expanding access to effective care.

The application relies on Phase 3 results from the VOLGA trial (NCT04960709), which demonstrated improved event-free and overall survival compared to radical cystectomy alone. No new safety signals were identified during this study period.

The players

FDA

The federal agency responsible for protecting public health by regulating the safety and efficacy of medical products.

AstraZeneca

A global biopharmaceutical company focusing on oncology therapies, including durvalumab.

The details

The regimen pairs durvalumab, a PD-L1 inhibitor, with enfortumab vedotin, a Nectin-4-directed antibody-drug conjugate that targets and delivers a microtubule inhibitor to cancer cells. Patients receive neoadjuvant enfortumab vedotin followed by perioperative durvalumab to eliminate tumor cells before and after radical cystectomy surgery.

September 25, 2026: FDA granted Priority Review.
Q4 2026: Expected regulatory decision.

Cancer
Sept. 28
New Guidelines Issued for Bladder Cancer Radiation
Cancer
Sept. 24
FDA Approved New Therapy for Advanced Kidney Cancer
Cancer
Sept. 26
FDA Application Withdrawn for Lung Cancer Drug Candidate

Health Landscape

This development follows an ongoing shift toward immunotherapy-based regimens in the treatment of muscle-invasive bladder cancer. The VOLGA trial marks a change in standard perioperative care by integrating targeted antibody-drug conjugates with immunotherapy.

If you or a loved one have been diagnosed with muscle-invasive bladder cancer and are not a candidate for cisplatin, discuss this emerging combination therapy with your oncologist. It is important to ask about clinical trials and how your specific cancer type may respond to this treatment pathway.

The takeaway

This potential new treatment offers a targeted approach for patients who cannot receive standard chemotherapy. Discuss your specific treatment plan and eligibility for new therapies with your physician.